NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,191.51 +428.48 (+2.41%) CRUDE OIL
79.47 +0.47 (+0.59%) GOLD FUTURES
2,324.10 +13.10 (+0.57%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,980.80 -1,638.41 (-3.44%)
Amgen Inc. (AMG.DE)
| Previous close | 255.20 |
| Open | 261.05 |
| Bid | 255.10 x 20000 |
| Ask | 256.25 x 9000 |
| Day's range | 255.90 - 261.05 |
| 52-week range | 196.60 - 306.00 |
| Volume | |
| Avg. volume | 572 |
| Market cap | 139.482B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 21.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.29 (3.24%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Reuters
Amgen investors await weight-loss drug data
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.
- Benzinga
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosimilars. Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. “The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said. Sandoz received FD
- Zacks
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
